Company
LON:IMM
ImmuPharma PLC is a biopharmaceutical company that specializes in the usage and development of biopolymers, specifically peptides. The company is dedicated to developing an innovative portfolio of peptide-based therapeutic drugs with a focus on autoimmunity/inflammation and anti-infectives.
306 stories · page 11 of 16
In all, 116 of the 200 patients with the life-threatening auto-immune disease have been through the 52-week process looking at the efficacy of Lupuzor
The FTSE 100 closed out Thursday up around 67 points at 7,555.
Archive
The big mover, up 64%, was Advanced Oncotherapy, which is building a next-generation proton therapy system
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Peter Allen will not be going back to the Future board room after February's AGM
The better-than-expected outcome reflects a trebling in the share price of Immupharma
Not much happening among the blue-chips but Image Scan and Future were among the big movers in the small caps sector
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
"We continue to believe that in order for an organisation to build and sustain a business-critical innovation ethos and competency, technology and consultancy need to be implemented in a joined-up way," said Imaginatik
Lupuzor is currently undergoing a phase III clinical trial 200 in patients in the US, Europe and Mauritius
There has been no news flow from FTSE 100 companies to speak of today
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
"I am particularly pleased to confirm funds released through the hedging facility will not carry any geographical restrictions. This means we will be able to deploy capital across our entire portfolio," said CEO, Matt Lofgran
Decision to start to manufacture commercial batches was taken in anticipation of the trial's successful outcome and to exploit 'fast track' status'
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Safestyle UK has more cash than it needs at present
We’ll know how effective Lupuzor is when the top line data is shared with the market in the first quarter of next year
In all 200 suffers were recruited to the trial and all of them have now past the three month stage.
